Drug intelligence / Profile preview

XKDCT-293

Development stage: Phase 1
Lead developer: Shenzhen Celconta Life Science
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

XKDCT-293 is a chimeric antigen receptor T cell (CAR-T) therapy targeting nectin-4. It is being developed by Shenzhen Celconta Life Science for the treatment of neoplasms, specifically advanced breast cancer that expresses nectin-4. The drug works as a nectin-4 inhibitor by engineering patient-derived T cells to recognize and attack cancer cells expressing the nectin-4 protein. As of June 2025, it is in Phase 1 clinical trials in China for patients with advanced breast cancer[1][2][3][4].

Other names: Nectin-4-CAR-T(Shenzhen Xiankangda Life)CT 293CT293CT-293

Targets

PVRL4 (Nectin cell adhesion molecule 4)

Beyond the preview

Go deeper on XKDCT-293.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XKDCT-293.

Explore the full profile